152 related articles for article (PubMed ID: 30389576)
1. Development of a simple new flow cytometric antibody-dependent cellular cytotoxicity (ADCC) assay with excellent sensitivity.
Tanaka M; Ishige A; Yaguchi M; Matsumoto T; Shirouzu M; Yokoyama S; Ishikawa F; Kitabayashi I; Takemori T; Harada M
J Immunol Methods; 2019 Jan; 464():74-86. PubMed ID: 30389576
[TBL] [Abstract][Full Text] [Related]
2. Validation of an ADCC assay using human primary natural killer cells to evaluate biotherapeutic products bearing an Fc region.
González-González E; Camacho-Sandoval R; Jiménez-Uribe A; Montes-Luna A; Cortés-Paniagua I; Sánchez-Morales J; Muñoz-García L; Tenorio-Calvo AV; López-Morales CA; Velasco-Velázquez MA; Pavón L; Pérez-Tapia SM; Medina-Rivero E
J Immunol Methods; 2019 Jan; 464():87-94. PubMed ID: 30395815
[TBL] [Abstract][Full Text] [Related]
3. Quantitating ADCC against adherent cells: Impedance-based detection is superior to release, membrane permeability, or caspase activation assays in resolving antibody dose response.
Tóth G; Szöllősi J; Vereb G
Cytometry A; 2017 Oct; 91(10):1021-1029. PubMed ID: 28945315
[TBL] [Abstract][Full Text] [Related]
4. Humanised IgG1 antibody variants targeting membrane-bound carcinoembryonic antigen by antibody-dependent cellular cytotoxicity and phagocytosis.
Ashraf SQ; Umana P; Mössner E; Ntouroupi T; Brünker P; Schmidt C; Wilding JL; Mortensen NJ; Bodmer WF
Br J Cancer; 2009 Nov; 101(10):1758-68. PubMed ID: 19904275
[TBL] [Abstract][Full Text] [Related]
5. Generation and preclinical characterization of an NKp80-Fc fusion protein for redirected cytolysis of natural killer (NK) cells against leukemia.
Deng G; Zheng X; Zhou J; Wei H; Tian Z; Sun R
J Biol Chem; 2015 Sep; 290(37):22474-84. PubMed ID: 26198633
[TBL] [Abstract][Full Text] [Related]
6. Cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity mediated by chimeric anti-GD3 monoclonal antibody KM871.
Liu Z; Lee FT; Hanai N; Smyth FE; Burgess AW; Old LJ; Scott AM
Cancer Immun; 2002 Oct; 2():13. PubMed ID: 12747758
[TBL] [Abstract][Full Text] [Related]
7. Evaluating Antibody-Dependent Cell-Mediated Cytotoxicity by Flow Cytometry.
van der Haar Àvila I; Marmol P; Cany J; Kiessling R; Pico de Coaña Y
Methods Mol Biol; 2019; 1913():181-194. PubMed ID: 30666607
[TBL] [Abstract][Full Text] [Related]
8. Reactive oxygen species induced by therapeutic CD20 antibodies inhibit natural killer cell-mediated antibody-dependent cellular cytotoxicity against primary CLL cells.
Werlenius O; Aurelius J; Hallner A; Akhiani AA; Simpanen M; Martner A; Andersson PO; Hellstrand K; Thorén FB
Oncotarget; 2016 May; 7(22):32046-53. PubMed ID: 27097113
[TBL] [Abstract][Full Text] [Related]
9. Development of a kinetic antibody-dependent cellular cytotoxicity assay.
Kamen L; Thakurta T; Myneni S; Zheng K; Chung S
J Immunol Methods; 2019 May; 468():49-54. PubMed ID: 30790564
[TBL] [Abstract][Full Text] [Related]
10. Development of a robust reporter-based ADCC assay with frozen, thaw-and-use cells to measure Fc effector function of therapeutic antibodies.
Cheng ZJ; Garvin D; Paguio A; Moravec R; Engel L; Fan F; Surowy T
J Immunol Methods; 2014 Dec; 414():69-81. PubMed ID: 25086226
[TBL] [Abstract][Full Text] [Related]
11. The human natural killer cytotoxic cell line NK-92, once armed with a murine CD16 receptor, represents a convenient cellular tool for the screening of mouse mAbs according to their ADCC potential.
Clémenceau B; Vivien R; Pellat C; Foss M; Thibault G; Vié H
MAbs; 2013; 5(4):587-94. PubMed ID: 23770975
[TBL] [Abstract][Full Text] [Related]
12. B-lymphoma cells escape rituximab-triggered elimination by NK cells through increased HLA class I expression.
Borgerding A; Hasenkamp J; Engelke M; Burkhart N; Trümper L; Wienands J; Glass B
Exp Hematol; 2010 Mar; 38(3):213-21. PubMed ID: 20056126
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-2 enhancement of cytotoxicity by humanized monoclonal antibody M195 (anti-CD33) in myelogenous leukemia.
Caron PC; Lai LT; Scheinberg DA
Clin Cancer Res; 1995 Jan; 1(1):63-70. PubMed ID: 9815888
[TBL] [Abstract][Full Text] [Related]
14. The anti-lymphoma effect of antibody-mediated immunotherapy is based on an increased degranulation of peripheral blood natural killer (NK) cells.
Fischer L; Penack O; Gentilini C; Nogai A; Muessig A; Thiel E; Uharek L
Exp Hematol; 2006 Jun; 34(6):753-9. PubMed ID: 16728280
[TBL] [Abstract][Full Text] [Related]
15. ChLpMab-23: Cancer-Specific Human-Mouse Chimeric Anti-Podoplanin Antibody Exhibits Antitumor Activity via Antibody-Dependent Cellular Cytotoxicity.
Kaneko MK; Nakamura T; Kunita A; Fukayama M; Abe S; Nishioka Y; Yamada S; Yanaka M; Saidoh N; Yoshida K; Fujii Y; Ogasawara S; Kato Y
Monoclon Antib Immunodiagn Immunother; 2017 Jun; 36(3):104-112. PubMed ID: 28504613
[TBL] [Abstract][Full Text] [Related]
16. Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody.
Chen Y; You F; Jiang L; Li J; Zhu X; Bao Y; Sun X; Tang X; Meng H; An G; Zhang B; Yang L
Oncotarget; 2017 Jun; 8(23):37128-37139. PubMed ID: 28415754
[TBL] [Abstract][Full Text] [Related]
17. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
Wu L; Adams M; Carter T; Chen R; Muller G; Stirling D; Schafer P; Bartlett JB
Clin Cancer Res; 2008 Jul; 14(14):4650-7. PubMed ID: 18628480
[TBL] [Abstract][Full Text] [Related]
18. CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations.
van Ojik HH; Bevaart L; Dahle CE; Bakker A; Jansen MJ; van Vugt MJ; van de Winkel JG; Weiner GJ
Cancer Res; 2003 Sep; 63(17):5595-600. PubMed ID: 14500400
[TBL] [Abstract][Full Text] [Related]
19. Development of a novel reporter gene assay to evaluate antibody-dependent cellular phagocytosis for anti-CD20 therapeutic antibodies.
Liu C; Yu C; Yang Y; Huang J; Yu X; Duan M; Wang L; Wang J
Int Immunopharmacol; 2021 Nov; 100():108112. PubMed ID: 34521023
[TBL] [Abstract][Full Text] [Related]
20. A Neutralizing Antibody Assay Based on a Reporter of Antibody-Dependent Cell-Mediated Cytotoxicity.
Wu Y; Li JJ; Kim HJ; Liu X; Liu W; Akhgar A; Bowen MA; Spitz S; Jiang XR; Roskos LK; White WI
AAPS J; 2015 Nov; 17(6):1417-26. PubMed ID: 26205082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
